Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis.

MLA

Weddell, Jake, et al. “Real-World Experience of IL-17Ai Drug Survival in a Large Cohort of Axial Spondyloarthritis and Psoriatic Arthritis.” Rheumatology Advances in Practice, vol. 8, no. 1, Feb. 2024, p. rkae018. EBSCOhost, https://doi.org/10.1093/rap/rkae018.

APA

Weddell, J., Din, N. R. A., Harrison, S. R., Michelena, X., McGonagle, D., Barr, A., Vandevelde, C., Freeston, J., & Marzo-Ortega, H. (2024). Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis. Rheumatology Advances in Practice, 8(1), rkae018. https://doi.org/10.1093/rap/rkae018

Chicago

Weddell, Jake, Naw Ra Aung Din, Stephanie R Harrison, Xabier Michelena, Dennis McGonagle, Andrew Barr, Claire Vandevelde, Jane Freeston, and Helena Marzo-Ortega. 2024. “Real-World Experience of IL-17Ai Drug Survival in a Large Cohort of Axial Spondyloarthritis and Psoriatic Arthritis.” Rheumatology Advances in Practice 8 (1): rkae018. doi:10.1093/rap/rkae018.